(MedPage Today) -- At the recent American Society of Hematology annual meeting, real-world analyses examined how polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is being adopted outside...
Read more











